Lauren Stopfer

Company: Aethon Therapeutics

Job title: Executive Director, Proteomics & Innovation

Seminars:

Cross-HLA Targeting of Synthetic Neoepitopes with T-Cell Engagers to Eradicate KRASG12C Inhibitor-Resistant Cancers 3:30 pm

• Development of high-specificity and high-affinity T-cell engaging bispecific antibodies (HapImmune antibodies) targeting KRASG12C inhibitor-modified HLA peptides (haptenpeptides, “p*MHCs”) • Direct detection of p*MHCs by mass spectrometry, detailed target characterization, and demonstrated in vitro/in vivo activity of HapImmune antibodies • Demonstration of the molecular-basis for cross-HLA recognition, examples spanning alleles within and across HLA supertypesRead more

day: Day 1